Kalpit Patel
Stock Analyst at B. Riley Securities
(1.48)
# 3,475
Out of 5,173 analysts
71
Total ratings
34.69%
Success rate
-8.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $117 | $77.37 | +51.22% | 6 | Dec 22, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $5 → $3 | $0.58 | +418.49% | 6 | Nov 25, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Peer Perform | n/a | $11.29 | - | 1 | Nov 18, 2025 | |
| CORT Corcept Therapeutics | Initiates: Peer Perform | n/a | $34.01 | - | 1 | Nov 18, 2025 | |
| JANX Janux Therapeutics | Initiates: Peer Perform | n/a | $13.93 | - | 1 | Nov 18, 2025 | |
| TNGX Tango Therapeutics | Initiates: Peer Perform | n/a | $19.21 | - | 1 | Nov 18, 2025 | |
| ACLX Arcellx | Initiates: Peer Perform | n/a | $114.54 | - | 1 | Nov 18, 2025 | |
| SMMT Summit Therapeutics | Initiates: Peer Perform | n/a | $15.83 | - | 1 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $42 | $44.17 | -4.91% | 1 | Nov 18, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Outperform | $75 | $32.39 | +131.55% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $96.57 | -22.34% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $107.40 | +2.42% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $6.82 | +75.95% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $4.34 | +222.58% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $21.77 | +69.96% | 1 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $26.29 | -8.71% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.58 | +121.52% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $5.47 | +64.53% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.20 | +92.31% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $8.55 | +367.84% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $2.57 | +16.73% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $27.60 | -27.54% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $4.09 | +633.50% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $24.28 | +48.27% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $1.67 | +5,305.41% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.57 | +600.39% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.08 | +365.12% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $9.15 | +992.90% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $24.69 | +203.77% | 2 | Sep 3, 2021 |
Kymera Therapeutics
Dec 22, 2025
Maintains: Buy
Price Target: $80 → $117
Current: $77.37
Upside: +51.22%
PDS Biotechnology
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.58
Upside: +418.49%
ORIC Pharmaceuticals
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $11.29
Upside: -
Corcept Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $34.01
Upside: -
Janux Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $13.93
Upside: -
Tango Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $19.21
Upside: -
Arcellx
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $114.54
Upside: -
Summit Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $15.83
Upside: -
Scholar Rock Holding
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $44.17
Upside: -4.91%
Soleno Therapeutics
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $32.39
Upside: +131.55%
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $96.57
Upside: -22.34%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $107.40
Upside: +2.42%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $6.82
Upside: +75.95%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $4.34
Upside: +222.58%
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $21.77
Upside: +69.96%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $26.29
Upside: -8.71%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.58
Upside: +121.52%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $5.47
Upside: +64.53%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.20
Upside: +92.31%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $8.55
Upside: +367.84%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $2.57
Upside: +16.73%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $27.60
Upside: -27.54%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $4.09
Upside: +633.50%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $24.28
Upside: +48.27%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $1.67
Upside: +5,305.41%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.57
Upside: +600.39%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.08
Upside: +365.12%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $9.15
Upside: +992.90%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $24.69
Upside: +203.77%